secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001701541-22-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Q3 2022 net loss $21.7M; cash $144.2M into Q3 2024
----------------------------------------------------------------

- Net loss $21.7M vs $35.1M YoY; R&D expenses fell to $15.8M from $27.6M.
- Cash, equivalents & investments $144.2M at Sep 30, 2022, vs $209.8M Dec 31, 2021.
- Net cash used in operations $16.5M for Q3 vs $26.5M a year ago; runway through Q3 2024.
- BDTX-1535 clinical update expected in 2023; IND for BDTX-4933 planned H1 2023.
- Appointed Melanie Morrison as SVP Development Operations in October 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/0001701541-22-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/bdtx-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001701541-22-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer